Changing chemo not beneficial for metastatic B.C. patients with elevated circulating tumor cells
- Posted: December 13, 2013
For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression, according to the results of a phase III clinical trial presented by researchers from the University of Michigan Comprehensive Cancer Center at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.